Washington Bud Company

Testimony on a cannabis commission showed disagreements over the body’s potential value; supporters emphasized the bill gave licensed producers the power to decide for themselves.

The sponsor made reasoned arguments for producer-led cannabis research, but industry members were divided over whether the time was right for a cannabis commodity commission.

Feedback on a bill to legalize out-of-state cannabis license ownership was divided: some companies anticipated benefits while others viewed the move as only helping larger entities.

A bill creating cannabis tax tiering received supportive testimony and many neutral suggestions from industry representatives welcoming a new conversation on product taxation.

The longtime Director of WSLCB planned to step down, CCRS 2.0 was on track to go live, and public comments touched on equity, traceability, transparency, and the cannabis economy.

A relatively quiet forum produced few remarks or questions on draft changes to cannabis ingredient and processing rules, which aimed to further regulate cannabinoids beyond THC.

Following introductions, members contemplated how to improve criminal history checks for social equity applicants and prepared to advise regulators to disregard drug offenses broadly.

Panelists with experience in drug prevention and behavioral science couldn’t reach consensus on the question of what makes cannabinoids impairing during a final dialogue on the topic.

Panelists from previous talks returned to field questions on identifying and regulating impairing cannabinoids, goals much more difficult to reach for cannabis than for alcohol.

After DOH representatives provided a brief background, two patients, a medical consultant, and a consultant trainer offered feedback on proposed changes to consultant certification rules.